India, March 5 -- Zydus Lifesciences, a global discovery-based life sciences company, has introduced ANVIMO (Letermovir), a groundbreaking solution for preventing Cytomegalovirus (CMV) infection in haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will be available in 240 mg and 480 mg dosages.
CMV infection is a major complication in transplant recipients, often leading to graft failure, reduced survival rates, and prolonged hospital stays. Existing treatments, such as ganciclovir and valganciclovir, are associated with significant side effects, including toxicity and bone marrow suppression. Letermovir offers a safer, well-tolerated, and effective alternative, improving transplant outcomes with fewer side ...